Aarti Pharmalabs Ltd (NSE: AARTIPHARM) and Alivus Life Sciences Ltd (NSE: ALIVUS) are both listed in the Pharmaceutical Contract Manufacturing Services industry. Aarti Pharmalabs has a market capitalisation of ₹8,060 Cr and Alivus Life Sciences ₹17,772 Cr, as of 9 Nov 2026. Their P/E ratios are 46.2 and 31.5 respectively. Return on equity is 8.49% for Aarti Pharmalabs and 18.36% for Alivus Life Sciences. Over one year, Aarti Pharmalabs's share price is up 7.6% and Alivus Life Sciences's is up 63.1%.
| Metric | Aarti Pharmalabs | Alivus Life Sciences |
|---|---|---|
| NSE Symbol | AARTIPHARM | ALIVUS |
| BSE Code | 543748 | 543322 |
| Share Price | ₹923.00 | ₹1,475.00 |
| Market Cap | ₹8,060 Cr | ₹17,772 Cr |
| P/E Ratio | 46.2 | 31.5 |
| Return on Equity | 8.49% | 18.36% |
| Return on Assets | 5.84% | 12.21% |
| Dividend Yield | 0.45% | 0.35% |
| Beta (1Y) | 0.51 | 0.35 |
| 1-Year Price Change | +7.6% | +63.1% |
| 3-Month Price Change | +12.2% | +7.3% |
| 52-Week Range | ₹585.00 – ₹1,002.40 | ₹819.00 – ₹1,554.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹610 Cr | ₹682 Cr |
| Quarterly Net Profit | ₹71 Cr | ₹197 Cr |
| Net Margin | 11.7% | 28.8% |
| EPS (Basic, Quarter) | ₹7.88 | ₹16.02 |
| Results Basis | consolidated | standalone |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for d…
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, res…
Alivus Life Sciences has a market capitalisation of ₹17,772 Cr, against ₹8,060 Cr for Aarti Pharmalabs as of 9 Nov 2026, about 2.2 times the size by market cap.
Aarti Pharmalabs has a P/E of 46.2 and Alivus Life Sciences a P/E of 31.5 as of 9 Nov 2026.
Aarti Pharmalabs has a return on equity of 8.49% and Alivus Life Sciences 18.36%.
Aarti Pharmalabs's share price is up 7.6% over one year and Alivus Life Sciences's is up 63.1%.
Aarti Pharmalabs reported revenue of ₹610 Cr and net profit of ₹71 Cr for Q2 FY27. Alivus Life Sciences reported revenue of ₹682 Cr and net profit of ₹197 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Pharmaceutical Contract Manufacturing Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.